Pulse Biosciences Inc Common Stock (DE)
Pulse Biosciences Inc Common Stock (DE) (PLSE): 10 pipeline candidates · ~14 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.2 months
D/E 0.23 · 0% dilution
Lead: Approved
10 candidates
N/A
2 buys · 7 sells (180d)
A transparent, data-derived signal for Pulse Biosciences Inc Common Stock (DE)across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$68.3M
Quarterly Burn
$14.6M
Runway
14.2 mo
Revenue
$401K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
94
Total value held
$166.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,631,704 | $35.2M |
| blackrock, inc. | 1,339,778 | $28.9M |
| bank of america corp /de/ | 866,061 | $18.7M |
| geode capital management, llc | 491,946 | $10.6M |
| massachusetts financial services co /ma/ | 462,899 | $10.0M |
| state street corp | 456,927 | $9.9M |
| balyasny asset management l.p. | 265,164 | $5.7M |
| griffin asset management, inc. | 225,177 | $4.9M |
| northern trust corp | 187,272 | $4.0M |
| citadel advisors llc | 168,050 | $3.6M |
Showing top 10 of 94 institutional holders of Pulse Biosciences Inc Common Stock (DE). Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Pulse Biosciences Inc Common Stock (DE)'s pipeline?
Pulse Biosciences Inc Common Stock (DE) (PLSE) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Pulse Biosciences Inc Common Stock (DE)'s lead drug candidate?
Pulse Biosciences Inc Common Stock (DE)'s most advanced tracked candidate is CellFX Console (Approved) for Dermatologic procedures requiring ablation and resurfacing of the skin (previous regulatory clearance); platform configured to accept disposable applicators for a variety of clinical applications including use with nsPFA Percutaneous Electrode System and cardiac applications.
What is Pulse Biosciences Inc Common Stock (DE)'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Pulse Biosciences Inc Common Stock (DE) has approximately 14.2 months of cash runway.
What is Pulse Biosciences Inc Common Stock (DE)'s market capitalization?
Pulse Biosciences Inc Common Stock (DE)'s market capitalization is approximately $1.8B.
Who is the CEO of Pulse Biosciences Inc Common Stock (DE)?
Mr. Paul Arthur LaViolette M.B.A. is the chief executive officer of Pulse Biosciences Inc Common Stock (DE) (PLSE).
Get the full picture on Pulse Biosciences Inc Common Stock (DE)
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.